Öfverholm I, Lin Y, Mondini J, Hardingz J, Bränström R, Tsagkozis P, Wirta V, Gellerbring A, Lindberg J, Chellappa V, Mayrhofer M, Haglund C, Haglund de Flon F, Wallander K
Cancers (Basel) 16 (22) 3816 [2024-11-13; online 2024-11-13]
The etiology of most mesenchymal tumors is unknown, and knowledge about syndromes with an increased risk of tumors in bone or soft tissue is sparse. We present a prospective germline analysis of 312 patients with tumors suspected of being sarcomas at a tertiary sarcoma center. Germline and tumor whole genome sequencing, tumor transcriptome, and methylome analyses were performed. Germline pathogenic or likely pathogenic variants associated with an increased risk of tumors were detected in 24 patients (8%), of which 11 (4%) harbored a detectable second hit in the tumor. Second hits were confirmed in genes with (NF1, RB1, TP53, EXT2, and SDHC) and without (ATM, CDC73, MLH1, MSH6, POLG, and KCNQ1) known association with mesenchymal tumor predisposition. Sarcomas from two Lynch syndrome patients showed mismatch repair deficiency, predicting a treatment response to immune checkpoint inhibitors (Level 1 biomarker according to the FDA (Federal Drug Administration) and ESMO (European Society for Medical Oncology)). None of the three CHEK2 carriers had a second hit in the tumor, suggesting a weak link to sarcoma. We conclude that second-hit analyses can be used in standard of care to identify syndrome-related tumors. This approach can help distinguish true manifestations of tumor syndromes from unrelated germline findings and enhance the understanding of germline predisposition in soft tissue tumors. Prospective screening using germline whole genome sequencing should be considered when comprehensive somatic sequencing is introduced into clinical practice.
Bioinformatics Support and Infrastructure [Collaborative]
Bioinformatics Support, Infrastructure and Training [Collaborative]
Clinical Genomics Stockholm [Service]
PubMed 39594770
DOI 10.3390/cancers16223816
Crossref 10.3390/cancers16223816
pii: cancers16223816
pmc: PMC11592761